Replies to post #142 on Navidea Biopharmaceuticals Inc (NAVBQ)

[petprodoc]

Mapping with riggs -what has been said

Point 1.You must find something that you wouldn’t have found without mapping

-Occult tumor was confirmed in 21% of the recurrent patients and 14% of primary patients

Point 2 Finding whatever you found that you wouldn’t have found otherwise has to make a difference to the patient’s outcome.

survival data from RIGS clinical trials in both recurrent and primary colorectal studies emerged from clinical investigators that confirmed the prognostic nature of RIGS-positive tissue

This BLA stage product seems like a good bet for seventy cents
a share